| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $9.7M | +34.2% | -23.1% |
| SG&A Expense | $4.6M | -1.6% | +8.4% |
| Operating Income | -$14.3M | -20.2% | +15.2% |
| Net Income | -$12.9M | -24.3% | +11.7% |
| EPS (Basic) | -$0.40 | -25.0% | +11.1% |
| EPS (Diluted) | -$0.40 | -25.0% | +11.1% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $32.5M | -23.2% | -57.8% |
| Short-term Investments | $84.2M | +1.3% | +11.6% |
| Current Assets | $119.5M | -6.1% | -24.0% |
| Total Assets | $128.4M | -6.6% | -26.5% |
| Current Liabilities | $9.1M | +26.2% | — |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$33.8M | — | — |
| Investing Cash Flow | -$9.8M | — | — |
| Financing Cash Flow | $275K | — | — |
| $119.3M |
| -8.4% |
| -30.1% |